Masimo announces Q3 earnings per share of $1.32, surpassing consensus estimate of $1.20
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Should l Buy MASI?
Q3 Financial Performance: Masimo reported Q3 revenue of $371.5 million, exceeding the consensus estimate of $366.9 million, with an 8% revenue growth and a 38% increase in EPS.
Operational Improvements: The company achieved a 450 basis point improvement in operating margin, attributed to sales growth and successful efficiency initiatives.
Strategic Moves: Masimo completed the sale of Sound United to Harman, using the proceeds for stock repurchase, and announced an expansion of its partnership with Philips.
Future Outlook: The CEO emphasized ongoing investments in the core healthcare business and plans to share more strategic details at the upcoming Investor Day on December 3rd.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MASI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MASI
Wall Street analysts forecast MASI stock price to rise
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 178.390
Low
162.00
Averages
188.40
High
210.00
Current: 178.390
Low
162.00
Averages
188.40
High
210.00
About MASI
Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Apple Wins Patent Dispute Against Masimo
- Patent Dispute Outcome: The U.S. International Trade Commission ruled in favor of Apple (AAPL) in its patent dispute with medical device maker Masimo (MASI), rejecting Masimo's request for an import ban on certain Apple Watch models, demonstrating Apple's legal strength in technology competition.
- Legal Battle History: Since 2021, Masimo has accused Apple of poaching key engineers and stealing its developed pulse oximetry technology, and despite launching multiple lawsuits over six years, nearly all claims have been dismissed, reflecting Apple's robust legal defense capabilities.
- Market Reaction: At the time of this announcement, retail sentiment around MASI and AAPL stocks remained in the 'bullish' territory, with MASI stock gaining 17% over the past 12 months and AAPL stock rising 37%, indicating strong market confidence in Apple.
- Future Outlook: Although Masimo can appeal the decision to the U.S. Court of Appeals for the Federal Circuit, Apple's victory may further solidify its leadership in the smartwatch market and reduce future legal risks.
See More
Masimo Secures $100M Patient Monitoring Contract
- Significant Contract Value: Masimo has secured a maximum fixed-price contract worth approximately $100 million for patient monitoring and capital equipment, reflecting strong demand and market confidence in the medical device sector.
- Extended Contract Duration: This award exercises the five-year option period under the existing five-year base contract, with the ordering period running through April 19, 2031, ensuring a stable revenue stream for Masimo in the coming years.
- Broad Customer Base: The contract supports customers across the Army, Navy, Air Force, Marine Corps, and federal civilian agencies, highlighting Masimo's critical position and influence in the defense medical equipment market.
- Clear Funding Source: The contract is funded through FY2026–2031 defense working capital funds, demonstrating the government's ongoing investment and trust in Masimo's products, further solidifying the company's market position.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Masimo Corporation for its sale to Danaher Corporation at $180.00 per share in cash, potentially violating federal securities laws and fiduciary duties to shareholders.
- Merger Transaction Review: CECO Environmental Corp.'s merger with Thermon Group Holdings, Inc. is expected to result in CECO shareholders owning approximately 62.5% of the combined entity, with Halper Sadeh LLC potentially seeking increased compensation for shareholders.
- Shareholder Rights Protection: Marine Products Corporation is being sold to MasterCraft Boat Holdings, Inc. for $2.43 per share in cash and 0.232 shares of MasterCraft common stock, prompting Halper Sadeh LLC to encourage shareholders to understand their legal rights and options.
- Investor Support: Halper Sadeh LLC represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, highlighting its crucial role in protecting investor rights.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Rivas's Background: Maria Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, where she oversaw the launch of multiple blockbuster medical products, and her expertise is expected to bolster Telix's capabilities in oncology and rare diseases.
- Jellison's Experience: William Jellison has over 30 years of corporate finance leadership experience, including serving as CFO of Stryker Corporation, where he managed international finance and M&A, and his financial acumen will provide critical strategic support for Telix.
- Strategic Implications: This board expansion aligns with Telix's evolution into a global commercial-stage biopharmaceutical company, reflecting the company's commitment to enhancing governance structures and increasing market competitiveness, which is expected to drive long-term growth in the biopharmaceutical industry.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Maria Rivas Background: Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, overseeing the launch of multiple blockbuster drugs, which will provide critical support for Telix's product development and market strategies.
- William Jellison Credentials: Jellison has over 30 years of corporate finance experience in large regulated environments, previously serving as CFO of Stryker, managing international finance and M&A, and his financial management expertise will enhance Telix's capital allocation efficiency.
- Strategic Implications: This board expansion aligns with Telix's evolution as a dual-listed global commercial-stage biopharmaceutical company, reflecting the company's commitment to improving governance structures and market competitiveness, which is expected to drive future business growth.
See More
TELIX ENHANCES BOARD WITH NEW DIRECTOR APPOINTMENTS
New Director Appointments: Telix has strengthened its board by appointing additional directors to enhance governance and strategic oversight.
Focus on Growth: The new appointments are part of Telix's strategy to support its growth initiatives and expand its operational capabilities.
See More
Apple Wins Patent Dispute Against Masimo
- Patent Dispute Outcome: The U.S. International Trade Commission ruled in favor of Apple (AAPL) in its patent dispute with medical device maker Masimo (MASI), rejecting Masimo's request for an import ban on certain Apple Watch models, demonstrating Apple's legal strength in technology competition.
- Legal Battle History: Since 2021, Masimo has accused Apple of poaching key engineers and stealing its developed pulse oximetry technology, and despite launching multiple lawsuits over six years, nearly all claims have been dismissed, reflecting Apple's robust legal defense capabilities.
- Market Reaction: At the time of this announcement, retail sentiment around MASI and AAPL stocks remained in the 'bullish' territory, with MASI stock gaining 17% over the past 12 months and AAPL stock rising 37%, indicating strong market confidence in Apple.
- Future Outlook: Although Masimo can appeal the decision to the U.S. Court of Appeals for the Federal Circuit, Apple's victory may further solidify its leadership in the smartwatch market and reduce future legal risks.
See More
Masimo Secures $100M Patient Monitoring Contract
- Significant Contract Value: Masimo has secured a maximum fixed-price contract worth approximately $100 million for patient monitoring and capital equipment, reflecting strong demand and market confidence in the medical device sector.
- Extended Contract Duration: This award exercises the five-year option period under the existing five-year base contract, with the ordering period running through April 19, 2031, ensuring a stable revenue stream for Masimo in the coming years.
- Broad Customer Base: The contract supports customers across the Army, Navy, Air Force, Marine Corps, and federal civilian agencies, highlighting Masimo's critical position and influence in the defense medical equipment market.
- Clear Funding Source: The contract is funded through FY2026–2031 defense working capital funds, demonstrating the government's ongoing investment and trust in Masimo's products, further solidifying the company's market position.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Masimo Corporation for its sale to Danaher Corporation at $180.00 per share in cash, potentially violating federal securities laws and fiduciary duties to shareholders.
- Merger Transaction Review: CECO Environmental Corp.'s merger with Thermon Group Holdings, Inc. is expected to result in CECO shareholders owning approximately 62.5% of the combined entity, with Halper Sadeh LLC potentially seeking increased compensation for shareholders.
- Shareholder Rights Protection: Marine Products Corporation is being sold to MasterCraft Boat Holdings, Inc. for $2.43 per share in cash and 0.232 shares of MasterCraft common stock, prompting Halper Sadeh LLC to encourage shareholders to understand their legal rights and options.
- Investor Support: Halper Sadeh LLC represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, highlighting its crucial role in protecting investor rights.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Rivas's Background: Maria Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, where she oversaw the launch of multiple blockbuster medical products, and her expertise is expected to bolster Telix's capabilities in oncology and rare diseases.
- Jellison's Experience: William Jellison has over 30 years of corporate finance leadership experience, including serving as CFO of Stryker Corporation, where he managed international finance and M&A, and his financial acumen will provide critical strategic support for Telix.
- Strategic Implications: This board expansion aligns with Telix's evolution into a global commercial-stage biopharmaceutical company, reflecting the company's commitment to enhancing governance structures and increasing market competitiveness, which is expected to drive long-term growth in the biopharmaceutical industry.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Maria Rivas Background: Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, overseeing the launch of multiple blockbuster drugs, which will provide critical support for Telix's product development and market strategies.
- William Jellison Credentials: Jellison has over 30 years of corporate finance experience in large regulated environments, previously serving as CFO of Stryker, managing international finance and M&A, and his financial management expertise will enhance Telix's capital allocation efficiency.
- Strategic Implications: This board expansion aligns with Telix's evolution as a dual-listed global commercial-stage biopharmaceutical company, reflecting the company's commitment to improving governance structures and market competitiveness, which is expected to drive future business growth.
See More
TELIX ENHANCES BOARD WITH NEW DIRECTOR APPOINTMENTS
New Director Appointments: Telix has strengthened its board by appointing additional directors to enhance governance and strategic oversight.
Focus on Growth: The new appointments are part of Telix's strategy to support its growth initiatives and expand its operational capabilities.
See More
